Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB.

J Clin Psychopharmacol. 2009 Aug;29(4):319-26. doi: 10.1097/JCP.0b013e3181acc372.

PMID:
19593168
2.

ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.

Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB.

Clin Pharmacol Ther. 2006 Dec;80(6):668-81.

PMID:
17178267
3.

Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.

Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS.

J Clin Pharm Ther. 2007 Dec;32(6):641-9. Erratum in: J Clin Pharm Ther. 2008 Feb;33(1):93. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
18021343
4.

Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

Yoo HD, Cho HY, Lee YB.

Br J Clin Pharmacol. 2010 Jan;69(1):27-37. doi: 10.1111/j.1365-2125.2009.03558.x.

5.

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.

Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK, Albers LJ, Reist C, Roy R, Walkes W, Afra P.

J Clin Psychopharmacol. 2001 Aug;21(4):398-407.

PMID:
11476124
6.

Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.

Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, Jonzier-Perey M, Baumann P.

Ther Drug Monit. 2001 Jun;23(3):228-31.

PMID:
11360030
7.

Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.

Zhang WV, D'Esposito F, Edwards RJ, Ramzan I, Murray M.

Drug Metab Dispos. 2008 Dec;36(12):2547-55. doi: 10.1124/dmd.108.023671. Epub 2008 Sep 22.

8.

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.

Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L.

Br J Clin Pharmacol. 1997 Nov;44(5):439-46.

9.

Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.

Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, Hai TN, Petzold MG, Björkman A, Ashton M, Gil JP.

Eur J Clin Pharmacol. 2009 Apr;65(4):355-63. doi: 10.1007/s00228-008-0573-8. Epub 2008 Nov 1.

PMID:
18979093
10.

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.

Czerwensky F, Leucht S, Steimer W.

Ther Drug Monit. 2015 Apr;37(2):152-60. doi: 10.1097/FTD.0000000000000119.

PMID:
25090458
11.

CYP-mediated clozapine interactions: how predictable are they?

Chetty M, Murray M.

Curr Drug Metab. 2007 May;8(4):307-13. Review.

PMID:
17504220
12.

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD.

J Acquir Immune Defic Syndr. 2006 May;42(1):52-60.

PMID:
16639344
13.

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L.

Clin Pharmacol Ther. 2002 Mar;71(3):141-52.

PMID:
11907488
14.

Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.

Hilli J, Rane A, Lundgren S, Bertilsson L, Laine K.

Fundam Clin Pharmacol. 2007 Aug;21(4):379-86.

PMID:
17635176
15.

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.

Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr.

Clin Pharmacol Ther. 1998 Sep;64(3):257-68.

PMID:
9757149
16.

Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr.

Clin Pharmacol Ther. 2003 Nov;74(5):437-47.

PMID:
14586384
17.

CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.

Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB.

Ther Drug Monit. 2008 Dec;30(6):689-99. doi: 10.1097/FTD.0b013e31818a2a60.

PMID:
18978522
18.

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".

Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr.

Clin Pharmacol Ther. 2000 Oct;68(4):375-83.

PMID:
11061577
19.

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A.

Drug Metab Dispos. 2010 Jan;38(1):92-9. doi: 10.1124/dmd.109.029132.

20.

The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.

van der Weide J, Steijns LS, van Weelden MJ.

Pharmacogenetics. 2003 Mar;13(3):169-72.

PMID:
12618594

Supplemental Content

Support Center